טוען...
Characteristics of Real‐World Metastatic Non‐Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval
BACKGROUND. Evidence from cancer clinical trials can be difficult to generalize to real‐world patient populations, but can be complemented by real‐world evidence to optimize personalization of care. Further, real‐world usage patterns of programmed cell death protein 1 (PD‐1) inhibitors following app...
שמור ב:
| הוצא לאור ב: | Oncologist |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
AlphaMed Press
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5905694/ https://ncbi.nlm.nih.gov/pubmed/29317551 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0353 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|